Dr. Adeel Khan
speaker
165 appearances
1 recordings
1 series
first heard Nov 2024
last heard Nov 2024
Dr. Adeel Khan’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Look, it's always about safety. Safety is always number one. Exosomes are so safe. And even mesenchymal stem cells have so much safety data around them, too. It's always about first do no harm. And this stuff does not have harm. And so why not try it as an alternative to opioids or to surgery for chronic pain, especially, right? Like it doesn't, to me, it baffles my mind, but it's very clear.
Unfortunately, do you know what the most profitable drug now is?
No, it's actually methotrexate. It made something like $26 billion last year. So it surpassed spattens.
It's an epidemic of autoimmune conditions, probably related to toxins in an environment, probably COVID, maybe everything else that's going on in the modern world. And so it's just an epidemic. And you and I both know you can treat many of these just through nutrition and lifestyle, but most doctors don't know anything about that. So of course they're just prescribing medications.
And we know these things, wouldn't you rather be on something that's going to regulate your immune system and fix it than just suppress it, which may cause cancer, right? Like it doesn't, the risk benefit, it just makes no sense, you know? And I think you always have to look at what's called number needed to treat versus number needed to harm.
And that's essentially just a fancy, fancy way of just saying benefit versus harm. And if you look at that for a lot of the pharmaceuticals, it's not that great. Um,
Yeah, because to me, then you have these interventions that we're seeing that are reducing inflammation, oxidative stress, that are helping with so many different chronic diseases and they don't have harm. So why not have them as a first line as opposed to going straight to a lot of these pharmaceuticals that have risk? And that to me is kind of the logic.
And on your note of Muse exosomes, the reason they're... superior to standard exosomes is simply because they're from that new cell lineage.
So when new cells are replicating and when they're growing, the soup that they're growing in, that's what we're isolating, which has the signaling profile, meaning that secretome, which we talked about earlier, is superior than just a standard mesenchymal stem cell. So it has a better profile, number one.
And number two, because it is from a stressed, enduring lineage too, meaning the exosomes can stick around longer than standard exosomes, which it cleared up pretty quickly.
Yeah, that was my take. Until I had the mu cells, that was my take more or less. I would only use the stem cells in very specific situations. But now that's changed because the mu stem cells are actually pluripotent, which means they, and they, new stem cells are very interesting because they act kind of like macrophages.
They actually eat, they gobble up damaged cells and then they turn into the new tissue. So they'll, for example, in the heart, they'll go to the heart, they'll eat the damaged cardiomyocytes, so like damaged heart cells, and then they'll actually regenerate new cardiomyocytes. So they're actually pluripotent, right? And that's the key difference because they're not just reducing inflammation.
And that's why new stem cells are, of course, more powerful than these exosomes because they're actually going to regenerate new tissue versus just reducing inflammation
which is what the old generation stem cells used to do and that's why when i was using the old generation stem cells i was kind of just using exosomes for the most part because i didn't see the point because i'm like you're just really reducing inflammation but now that we have something that's pluripotent if i'm injecting it for something degenerative and i actually want to regenerate something new then i'm going to use the stem cells so for example with advanced osteoarthritis
If we want to actually stimulate cartilage regeneration, using the new stem cells makes a lot more sense. But if you just want to reduce inflammation, then you can just use the exosome.
Yeah, and there's studies out there showing that the exosomes can create a favorable microenvironment for stem cell differentiation and for stem cells to do their job, basically. So that's why I tend to just combine them because the exosomes are only there for like minutes to hours, you know, like we said, like they're cleared up pretty quickly.
But then what they do is they go in there, they reduce inflammation, they make it a better microenvironment so that the stem cells can do their job more effectively.
So the results since the new stuff has been honestly incredible. And as a physician, you always want your patients to get better. And now we have much more consistent results. With the older stuff, the results were a bit more inconsistent, meaning some people would get better, some people wouldn't. Whereas this stuff just tends to be reproducible.
And the way we do it is it's still very specialized, right? And this is the problem too. There's so many stem cell clinics that they don't know how to inject properly. You have to have a very high skill level You can't just, yes, there is a certain homing mechanism, but at the end of the day, the treatments are going to work better if you get them to where they need to go.
So for example, if you have a rotator cuff in your shoulder and you don't get the right spot, your results aren't going to be as good as getting it right in the right spot. So, and that takes a skilled, that takes a very skilled, you know, how it's skilled. It'd be very skilled at ultrasound and you have to have a high level of proficiency to be able to do that image guided injection.
Showing 81–100 of 165 · page 5 of 9
← Previous
Next →